|
|
|
| Managing Mergers With Sail's Guillaume Pfefer, Ph.D | While you might be aware that Sail Biomedicines was formed in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde. What you likely haven’t heard is the inside story of how the merger was executed. On the Business of Biotech, CEO Dr. Guillaume Pfefer takes us under the hood of Sail Biomedicines and its mission to marry evolution and AI to develop programmable medicines based on eRNA. |
|
|
|
|
By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy. |
|
|
|
Startup biotech and pharmaceutical companies can benefit from basing themselves in locations where “chance” meetings with decision makers and potential collaborators are more likely to occur. The benefits of proximity between startups and Big Pharma go both ways. |
|
|
|
|
|
|
|
| Small Is Powerful And Sustained | Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance. |
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
